Select Page

ADCETRIS ® (brentuximab vedotin) for injection, for intravenous use. Initial U.S. approval: 2011

ADCETRIS ® (brentuximab vedotin) for injection, for intravenous use. Initial U.S. approval: 2011

ADCETRIS is a Anti Cancer medicine. ADCETRIS is used to treat Hodgkin lymphoma.
ADCETRIS ® (brentuximab vedotin) for injection, for intravenous use. Initial U.S. approval: 2011
ADCETRIS is a CD30-directed antibody-drug conjugate indicated for treatment of patients with:
• Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates.
• Systemic anaplastic large cell lymphoma after failure of at least one prior multi-agent chemotherapy regimen. Accelerated approval was granted for the above indications based on overall response rate. An improvement in patient-reported outcomes or survival has not been established. Continued approval for these indications may be contingent upon verification and description of clinical benefit in confirmatory trials.
For injection: 50 mg lyophilized powder in a single-use vial
Manufactured By: Seattle Genetics, Inc.
Prescribing Information URL: Click Here

Procedure to buy ADCETRIS ® (brentuximab vedotin) for injection?
To buy ADCETRIS ® (brentuximab vedotin) for injection, patients can simply fill the order form or can send mail at or can also send Whatsapp message at +91 96677 50889. You will get reply within few hours with pricing and procedure details. Note:- the order will be confirmed only after the receipt of valid prescription of doctor.


Brentuximab vedotin (INN, trade name Adcetris) is an antibody-drug conjugate medication used to treat relapsed or refractory Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL). It selectively targets tumor cells expressing the CD30 antigen, a defining marker of Hodgkin lymphoma and ALCL (a type of T cell non-Hodgkin lymphoma). The drug is being jointly marketed by Millennium: The Takeda Oncology Company outside the US, and Seattle Genetics in the US.
In August 2011, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the biologics license application (BLA) submitted by Seattle Genetics for the use of brentuximab vedotin in the treatment of relapsed HL and ALCL.
In October 2012, the European Medicines Agency (EMA) gave it conditional marketing authorization for relapsed or refractory HL and ALCL.
In November 2017, the FDA approved brentuximab vedotin as a treatment for patients with cutaneous T-cell lymphoma (CTCL) who have received prior systemic therapy.This approval is for patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) and CD30-expressing mycosis fungoides (MF).
In March 2018, the FDA approved brentuximab vedotin to treat adults with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy.
In November 2018, the FDA expanded the approved use of brentuximab vedotin in combination with chemotherapy for adults with certain types of peripheral T-cell lymphoma (PTCL). This is the first FDA approval for treatment of newly diagnosed PTCL.


There are no reviews yet.

Be the first to review “ADCETRIS ® (brentuximab vedotin) for injection, for intravenous use. Initial U.S. approval: 2011”

Your email address will not be published.

Anti-Cancer Medicine Supplier.

Bionique Healthcare is a consulting pharmaceutical company which assist Patients in accessing medicines in India. Bionique Healthcare facilitates such access only against valid prescriptions in conformity with all local laws and regulations.

Patients/ Clinicians / Researchers can contact Bionique at +91 9667750889 or write to at –

Product Disclaimer

Bionique Healthcare does not manufacture, supply, re-sell or retail any drugs or medicines. All trademarks and other intellectual property in relation to drugs and medicines supplied to you by suppliers are owned by their respective manufacturer or licensee. 

Bionique Healthcare does not lay any claim on them.